Active surveillance (AS) is increasingly utilized for low-risk prostate cancers, to delay or avoid treatment.
To (1) describe uptake and surveillance intensity of real-world use of AS and compare with national guidelines, and (2) describe transitions from conservative to curative treatment by different indications of disease progression.